“Every patient I’ve prescribed it (Hydroxychloroqine) to has been very, very ill and within 8 to 12 hours, they were basically symptom-free,” said Los Angeles doctor Dr. Anthony Cardillo, adding “So clinically I am seeing a resolution.”
Hydroxychloroqine – a cheap, widely-prescribed anti-malaria drug which was deemed safe for decades until it showed efficacy treating coronavirus – needs to be made “widely available and promoted immediately for physicians to prescribe,” according Yale epidemiologist Dr. Harvey Risch.
The combination of HCQ+AZ “preferably with zinc” should be “standard outpatient treatment,” Risch insists.
In a Wednesday manuscript detailing how high-risk COVID-19 patients should be treated, Risch notes that the combination of hydroxychloroquine (HCQ) and the antibiotic azithromycin (AZ) “has been widely misrepresented in both clinical reportsand public media,” and that “Five studies, including two controlled clinical trials, have demonstrated significant major outpatient treatment efficacy.”
Has already been used as standard-of-care in more than 300,000 older adults
Hydroxychloroquine+azithromycin has been used as standard-of-care in more than 300,000 older adults with multi comorbidities, with estimated proportion diagnosed with cardiac arrhythmias attributable to the medications 47/100,000 users, of which estimated mortality is <20%,9/100,000 users, compared to the 10,000 Americans now dying each week. – Dr. Harvey Risch
See entire article, including Dr. Risch’s manuscript:
Thanks to Stephen Bird for this link
The post Yale Epidemiologist: Hydroxychloroquine Should Be ‘Widely Available And Promoted Immediately’ appeared first on Ice Age Now.
via Ice Age Now
June 2, 2020 at 08:58AM